{
    "doi": "https://doi.org/10.1182/blood.V110.11.1899.1899",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=895",
    "start_url_page_num": 895,
    "is_scraped": "1",
    "article_title": "Rituximab (R) in Addition to Dose-Dense Chemotherapy MegaCEOP and Intensification with R-MAD Followed by High Dose Chemotherapy BEAM with Autologous Stem Cell Transplantation (ASCT) Is Safe and Effective in Untreated High Risk Diffuse Large B-Cell Lymphoma (DLBCL). ",
    "article_date": "November 16, 2007",
    "session_type": "Clinical Results-Autologous Transplantation",
    "abstract_text": "Introduction: The addition of R to dose-dense chemotherapy CHOP and to high-dose chemotherapy seems to improve the outcome of advanced stage DLBCL. Patients and methods: From August 2000 to September 2006, 120 previously untreated patients (pts) <61 years affected by aggressive DLBCL were enrolled into 12 GIMURELL centers. Inclusion criteria were: advanced stage II, III-IV with age-adjusted (aa)-IPI score 2\u20133 or BM involvement (any aa-IPI score), viral markers negativity. Treatment plan consisted in a dose-dense chemoimmunotherapy R-MegaCEOP (R 375 mg/m 2 d1, CTX 1200 mg/m 2 + EPI 110 mg/m 2 + VCR 1.4 mg/m 2 d3 and PDN 40 mg/m 2 dd3\u20137) every 14 days with G-CSF support for 4 courses; pts in CR or PR received two courses of intensified chemotherapy R-MAD (Mitoxantrone 8 mg/m 2 + ARA-C 2000 mg/m 2 /12h + Dexamethasone 4 mg/m 2 /12h dd1\u20133 and R 375 mg/m 2 d4 and before peripheral blood stem cell harvest as in vivo purging) followed by ASCT with BEAM as conditioning regimen \u00b1 IF-RT. All pts received antibacterial and antifungal prophylaxis throughout the whole treatment. In pts with BM and/or CNS risk involvement, 4 IT-MTX 15 mg were planned as intrathecal prophylaxis. Results: All 120 pts were evaluable: median age 47 years (19\u201360); 65 males and 55 females; 6% were at Low-Intermediate, 52% at Intermediate-High and 42% at High risk according to aa-IPI score; PS \u22652 65%, 27% BM involvement, 48% bulky disease, 80% LDH >normal and stage II/III/IV 8/19/73% respectively. Complete response at the end of treatment was achieved in 98 pts (82%), PR in 5 (4%), 12 (10%) did not respond and 5 (4%) died of toxicity. IF-RT was performed as consolidation of bulky disease or residual disease on 36% of pts. With a median follow-up of 42 months, 4-yr FFS and 4-yr OS rates were: 77% and 80%. In 101 pts (84%), PBSC yeald was good, with a median of 9.7 \u00d7 10 6 cells CD34/kg (range 2.5\u201356.3). Nineteen pts (16%) were not autografted: 5 because of inadequate PBSC yield, 9 of progression disease and 5 of toxicity. All 101 pts who underwent ASCT achieved a complete hematological engraftment with a median of 9 days (3\u201327) to neutrophil counts >0.5 \u00d7 10 9 /L and a median of 14 days (1\u201372) to a self-sustaining platelet count >50 \u00d7 10 9 /L. Transfusional support was: platelets and red-cell package respectively in 8% and 24% of pts during 4 R-MegaCEOP, 92% and 70% during 2 R-MAD and 96% and 74% during BEAM consolidation. Few severe toxicities (WHO grade 3\u20134) were reported; most frequent (12%) were infection and mucositis during R-MAD and BEAM phase. Five patients died of toxicity due to: E.coli sepsis in 2 pts respectively after R-MegaCEOP and R-MAD, one of sepsis ndd after R-MAD, one of Staphilococcus pneumonia after R-MAD and one of P.aeruginosa pneumonia after BEAM regimen. There are no secondary MDS or ANLL or solid tumour. Conclusions: This study suggests that Rituximab as adjuvant to dose-dense and high dose chemotherapy with ASCT support is effective and safe in high risk DLBCL.",
    "topics": [
        "autologous stem cell transplant",
        "chemotherapy regimen",
        "diffuse large b-cell lymphoma",
        "dose-dense chemotherapy",
        "rituximab",
        "brachial plexus neuritis",
        "toxic effect",
        "pneumonia",
        "sepsis",
        "anti-bacterial agents"
    ],
    "author_names": [
        "Annalisa Chiappella",
        "Giuseppe Rossi",
        "Maria Giuseppina Cabras",
        "Anna Marina Liberati",
        "Giovannino Ciccone",
        "Flavia Salvi",
        "Emanuele Angelucci",
        "Barbara Botto",
        "Antonella Darbesio",
        "Roberto Freilone",
        "Lorella Orsucci",
        "Vincenzo Pavone",
        "Enrico Maria Pogliani",
        "Umberto Ricardi",
        "Delia Rota-Scalabrini",
        "Anna Tonso",
        "Alessandra Tucci",
        "Eugenio Gallo",
        "Umberto Vitolo"
    ],
    "author_affiliations": [
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "Unit of Cancer Epidemiology, CPO Piemonte, Torino, Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO San Giovanni Battista, Torino"
        ]
    ],
    "first_author_latitude": "45.0733813",
    "first_author_longitude": "7.685226799999999"
}